NCT00645606View on ClinicalTrials.gov

Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia

PHASE3CompletedINTERVENTIONAL

Enrollment

542

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2014

Study Completion Date

July 31, 2017

Conditions

Leukemia

Interventions

BIOLOGICAL

Rituximab

rituximab :500 mg/m² every 8 weeks during 2 years

Trial Locations (1)

37044

French Innovative leukemia Organization, Tours

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

collaborator

French Innovative Leukemia Organisation

OTHER

lead

University Hospital, Tours

OTHER

NCT00645606 - Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter